Article

Cognitive Rehabilitation Improves Quality of Life in Patients With MS


 

References

Dr. DeLuca added that patients with MS who have low cognitive reserve show greater impairment in cognition than those with high cognitive reserve, despite displaying similar levels of brain atrophy on MRI. “People who develop a brain that’s more resistant to the expression of MS will be much less likely to show these cognitive problems,” he said.

This finding has significant implications for the cognitive rehabilitation of patients with MS. Patients might build cognitive reserve through intellectual hobbies such as reading, art, and music, as well as by engaging in aerobic exercise.

For a young person diagnosed with MS, “building a cognitive reserve is going to be the very backbone of cognitive rehabilitation,” said Dr. DeLuca. “It may not be protective against disease progression, but it could be protective against the expression of the disease.”

Dr. DeLuca emphasized that cognitive rehabilitation influences the family life, employment, social relationships, and everyday life of patients. “Cognitive interventions can have a profound effect on the life of persons with MS, and that’s something we really need to focus on,” he concluded.


—Lauren LeBano

Click here to listen to an accompanying audio interview.

Pages

Recommended Reading

Alemtuzumab Will Help Clinicians Treat Patients With MS More Effectively—By Mark Gudesblatt, MD
ICYMI Multiple Sclerosis
Alemtuzumab May Be Superior to Interferon Beta-1a in Patients With MS—Results From the CARE-MS II Study
ICYMI Multiple Sclerosis
Jeffrey A. Cohen, MD, Describes His Comparison of Alemtuzumab and Interferon Beta-1a in Patients With Multiple Sclerosis
ICYMI Multiple Sclerosis
Laquinimod May Be Effective for the Long-Term Management of Multiple Sclerosis
ICYMI Multiple Sclerosis
Data Are Unclear About the Effectiveness of Laquinimod in Multiple Sclerosis—by Stuart Cook, MD
ICYMI Multiple Sclerosis
Tool Allows MS Patients to Assess How Their Impairment Compares to That of Other Patients With Same Disease Duration
ICYMI Multiple Sclerosis
Combined Use of Interferon beta-1a and Glatiramer Acetate May Not Be Superior to Glatiramer Acetate Alone in Reducing MS Relapses
ICYMI Multiple Sclerosis
The CombiRx Trial Could Shed Light on the MS Disease Process—by Richard A. Rudick, MD
ICYMI Multiple Sclerosis
In Vitro Fertilization Increases Risk of Multiple Sclerosis Relapse
ICYMI Multiple Sclerosis
In Utero Exposure to Disease-Modifying MS Drugs May Harm Offspring
ICYMI Multiple Sclerosis